Rodman & Renshaw initiates Hemab stock with buy on therapy potential

Rodman & Renshaw initiated coverage on Hemab Therapeutics (NASDAQ:COAG) with a buy rating and $56.00 price target, citing potential of sutacimig for Glanzmann thrombasthenia. The company is also developing treatments for Von Willebrand disease. Hemab has a strong balance sheet with a current ratio of 35.85. Recent phase 2 data showed promising results, leading H.C. Wainwright to raise its price target to $60.

Original reporting
Published Oct 12, 2026, 12:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 12, 2026, 12:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$COAG
Bullish
high confidence
Mentioned
$COAG
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$COAGBullishMed
01

Why it matters

The Phase 2 results and analyst upgrades provide fresh catalysts that could move the stock.

02

Market read

New clinical data and analyst upgrades create a short-term bullish catalyst for COAG.

03

What to watch

Potential regulatory delays and competition from larger hematology firms could limit upside.

Relevance 8/10Novelty 8/10Timing: today

Background

Hemab Therapeutics focuses on coagulation disorders, a niche with unmet needs.

Company-level read

Ticker impact

$COAGBullishHigh confidence
Context

Rodman & Renshaw initiates coverage with a buy rating and $56 target, citing positive Phase 2 data for sutacimig and analyst upgrades.

Expected impact

upward pressure as market prices in the favorable Phase 2 results and higher price targets.

Evidence & confidence

Phase 2 data showing reduced bleed rates and analyst price target lifts suggest improved outlook, prompting investors to add positions.

Market effects

Positive data may boost sentiment in the rare bleeding disorder biotech niche.

Limited to US biotech investors; no broader regional effect.

Modest, confined to specialty pharma sector.

Counterpoint

If Phase 3 fails to meet endpoints, the recent hype could reverse sharply.

Key entities

  • Hemab Therapeutics Holdings

    Developer of sutacimig for Glanzmann thrombasthenia and von Willebrand disease.

  • Rodman & Renshaw

    Initiated coverage with a buy rating.

  • H.C. Wainwright

    Raised price target to $60 after Phase 2 data.

Related articles

$COAGMed

Hemab Therapeutics Holdings Inc (COAG) (Q3 2026) Earnings Call Highlights: Pivotal SOLARA

Hemab Therapeutics (COAG) discussed its SOLARA Phase III trial and HMB002 data in its Q3 2026 earnings call. CEO Benny Sorensen highlighted a 50%+ reduction in annualized treated bleed rate for von Willebrand disease, with data covering Type 1 and 2A patients. The trial requires a minimum annualized treated bleed rate of four at entry. HMB002 aims to correct underlying pathophysiology and is monitorable by clinicians.

$COAGMedAI 8/10

Hemab (COAG) Q3 2026 Earnings Call Transcript

Hemab (COAG) reported Q3 2026 progress, including Phase I trial initiation for HMB-003, Phase III trial start for sutacimig in Glanzmann thrombasthenia, and preclinical data for HMB-002. The company added Keli Walbert to its board and is building its commercial strategy. Sutacimig showed promising results in reducing bleeds, and HMB-003 aims to address heavy menstrual bleeding, a condition affecting millions of women.

$COAGMedAI 8/10

What Hemab Therapeutics (COAG) Said on Its Q3 Earnings Call

Hemab Therapeutics (COAG) reported a Q3 net loss of $27.3 million, up from $17.1 million a year earlier. The company plans to present updated Phase 2b data for its Factor VII deficiency treatment and new data for its von Willebrand disease treatment in 2027. Preclinical data for its heavy menstrual bleeding candidate will also be presented in December. R&D expenses rose to $24.6 million, driven by clinical program advances.

High

Why is Hemab Therapeutics stock sliding today?

Hemab Therapeutics (HMAB) shares fell 5.3% premarket after reporting a wider Q3 2026 net loss of $27.3M ($0.58/share), up from $17.1M YoY, due to higher R&D and admin costs. CEO Benny Sørensen noted pipeline progress, including a Phase 3 study start. Cash reserves were $430.2M. LifeSci Capital initiated coverage with an Outperform rating and $65 target. Broader market declines also pressured the stock.

Med

Hemab Therapeutics Posts Q3 2026 Net Loss of $27.3 Million

Hemab Therapeutics reported a Q3 2026 net loss of $27.3M, up from $17.1M a year earlier, due to increased R&D and administrative expenses. The company had $430.2M in cash and expects it to last until 2029. Key developments include a Phase 3 trial launch for sutacimig and a Phase 1 trial for HMB-003.

$COAGMedAI 8/10

Hemab Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Hemab Therapeutics Holdings, Inc. (COAG) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Hemab Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update Dosed first participant in Phase 1 clinical trial of HMB-003 for management of heavy menstrual bleeding, a condition affecting more than 23 million women in the U.S. alone A